Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA.

Ann Oncol. 2013 Dec;24(12):3028-34. doi: 10.1093/annonc/mdt406. Epub 2013 Nov 4. Review.

PMID:
24190964
2.

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J.

Cochrane Database Syst Rev. 2013 Jul 9;(7):CD006910. doi: 10.1002/14651858.CD006910.pub2. Review.

PMID:
23835762
3.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

4.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
5.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators.

Lancet. 2003 Jun 21;361(9375):2099-106.

PMID:
12826431
6.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Lawrie TA.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004706. doi: 10.1002/14651858.CD004706.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;(12):CD004706.

7.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.

Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.

8.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. Lancet Oncol. 2015 Feb;16(2):e55.

PMID:
25481791
9.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC.

Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. Review.

PMID:
26676202
10.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004706. doi: 10.1002/14651858.CD004706.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD004706.

PMID:
19588360
11.

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

Wuntakal R, Seshadri S, Montes A, Lane G.

Cochrane Database Syst Rev. 2016 Jun 29;(6):CD011322. doi: 10.1002/14651858.CD011322.pub2. Review.

PMID:
27356090
12.

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M.

Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Review.

PMID:
25232001
13.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004706. doi: 10.1002/14651858.CD004706.pub2. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004706.

PMID:
19160239
14.

Management of platinum-sensitive recurrent ovarian cancer.

Pfisterer J, Ledermann JA.

Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6. Review.

PMID:
16716798
15.

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

Lawrie TA, Rabbie R, Thoma C, Morrison J.

Cochrane Database Syst Rev. 2013 Oct 21;(10):CD010482. doi: 10.1002/14651858.CD010482.pub2. Review.

PMID:
24142521
16.

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.

Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR,; NCIC CTG; EORTC GCG.

Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41.

PMID:
15839957
18.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.

PMID:
24637997
19.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
20.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

Supplemental Content

Support Center